

Pharmacy Benefact

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

Number 891 • September 2020

Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Apo-Ibuprofen 300 mg Tablet (DIN 00441651) and Apo-Ibuprofen 400 mg Tablet (DIN 00506052) manufactured by Apotex Inc., Advil 200 mg Tablet (DIN 01933558) manufactured by Pfizer Consumer Healthcare was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Apotex Inc. has advised Alberta Blue Cross that the shortage of Apo-Ibuprofen 400 mg Tablet (DIN 00506052) has been resolved. These products were removed from the Critical Supply Product List **September 1, 2020**.

As a result, Advil 200 mg Tablet (DIN 01933558) will no longer be considered a temporary benefit for the *ADBL* after **September 30, 2020**.

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Sivem Pharmaceuticals ULC, Sandoz Canada Inc., and Teva Canada Limited that the shortages for Losartan 25 mg Tablet (DIN 02388790), Sandoz-Losartan 25 mg Tablet (DIN 02313332), and Teva-Losartan 25 mg Tablet (DIN 02380838) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 30, 2020**. The following grouping was removed from the Critical Supply Product List **September 1, 2020**.

LOSARTAN POTASSIUM

25 MG TABLET

00002379058	APO-LOSARTAN	APX	\$ 0.1616
00002403323	AURO-LOSARTAN	AUR	\$ 0.1616
00002445964	BIO-LOSARTAN	BMD	\$ 0.1616
00002398834	JAMP-LOSARTAN	JPC	\$ 0.1616
00002388790	LOSARTAN	SIV	\$ 0.1616
00002405733	MINT-LOSARTAN	MPI	\$ 0.1616
00002309750	PMS-LOSARTAN	PMS	\$ 0.1616
00002313332	SANDOZ LOSARTAN	SDZ	\$ 0.1616
00002424967	SEPTA-LOSARTAN	SEP	\$ 0.1616
00002380838	TEVA-LOSARTAN	TEV	\$ 0.1616
00002182815	COZAAR	MFC	\$ 1.4140

Alberta Blue Cross has been advised by Sivem Pharmaceuticals ULC, Sandoz Canada Inc., and Teva Canada Limited that the shortages for Losartan 100 mg Tablet (DIN 02388812), Sandoz-Losartan 100 mg Tablet (DIN 02313359), and Teva-Losartan 100 mg Tablet (DIN 02357976) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 30, 2020**. The following grouping was removed from the Critical Supply Product List **September 1, 2020**.

continued on next page ...

... continued from previous page

LOSARTAN POTASSIUM

100 MG TABLET

00002353512	APO-LOSARTAN	APX	\$ 0.1616
00002403358	AURO-LOSARTAN	AUR	\$ 0.1616
00002445980	BIO-LOSARTAN	BMD	\$ 0.1616
00002398850	JAMP-LOSARTAN	JPC	\$ 0.1616
00002388812	LOSARTAN	SIV	\$ 0.1616
00002405768	MINT-LOSARTAN	MPI	\$ 0.1616
00002309777	PMS-LOSARTAN	PMS	\$ 0.1616
00002313359	SANDOZ LOSARTAN	SDZ	\$ 0.1616
00002424983	SEPTA-LOSARTAN	SEP	\$ 0.1616
00002357976	TEVA-LOSARTAN	TEV	\$ 0.1616
00002182882	COZAAR	MFC	\$ 1.4140

Alberta Blue Cross has been advised Sanis Health Inc., Sandoz Canada Inc. and Teva Canada Limited that the shortages for Lisinopril/HCTZ (Type Z) 20 mg/25 mg Tablet (DIN 02362961), Sandoz- Lisinopril/HCT 20 mg/25 mg Tablet 100 mg Tablet (DIN 02302381) and Teva-Lisinopril/HCTZ (Type Z) 20 mg/25 mg Tablet (DIN 02301784), respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 5, 2020**. The following grouping was removed from the Critical Supply Product List **September 2, 2020**.

LISINOPRIL/ HYDROCHLOROTHIAZIDE

20 MG / 25 MG TABLET

00002362961	LISINOPRIL/HCTZ (TYPE Z)	SNS	\$ 0.2503
00002302381	SANDOZ LISINOPRIL HCT	SDZ	\$ 0.2503
00002301784	TEVA-LISINOPRIL/HCTZ (TYPE Z)	TEV	\$ 0.2503
00002045729	ZESTORETIC	AZC	\$ 1.1159

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php

